DNA
Ginkgo Bioworks Holdings
10.30$
+19.5%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -39.0% | +0.2% | +34.7% | -0.9% | -8.8% | -1.8% | +2.8% | -10.3% | -3.6% | -6.3% | -3.8% | – | |
| – | -18.5% | -4.8% | -8.9% | -62.7% | +48.4% | -0.6% | +8.9% | -19.8% | +17.9% | -24.6% | -52.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -99.3% | +1,784.6% | -1,767.4% | – | -630.7% | – | – | -271.2% | – | – | – | |
| – | -21.3% | +94.7% | +302.9% | -44.2% | -9.1% | -44.4% | -99.5% | +20,057.9% | +100.1% | -87.4% | +35.5% | – | |
| – | +1,280.5% | -74.1% | +121.6% | -62.0% | +28.3% | +1,418.4% | -67.8% | +14.0% | – | -75.7% | -52.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | +0.0% | -100.0% | – | – | +88.7% | – | – | – | |
| – | – | – | – | – | +1.5% | +2.0% | -52.7% | -75.5% | +4.2% | -24.0% | -100.0% | – | |
| – | +100.6% | +33.7% | -73.3% | +105.8% | -56.3% | +2.0% | -52.7% | – | -18.1% | -100.2% | – | – | |
| – | – | – | – | – | – | – | – | – | – | -143.6% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.